A Phase 1 Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 27 Sep 2016
At a glance
- Drugs Tarextumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors OncoMed Pharmaceuticals
- 09 Apr 2013 Status changed from active, no longer recruiting to completed, according to OncoMed Biosciences.
- 28 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 28 Mar 2013 Planned end date changed from 1 Jun 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.